Evidence map›Paper›PMID 26788096›Full record

ArticleArchives of medical science : AMS2015

Ectopic expression of follicle-stimulating hormone receptors in thyroid tumors.

Marek Pawlikowski, Maria Jaranowska, Hanna Pisarek, Robert Kubiak, Julita Fuss-Chmielewska, Katarzyna Winczyk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of medical science : AMS, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. FSH, bone, belly and brain.The Journal of endocrinology · 2024
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Primary adrenal schwannoma with catecholamine hypersecretion.Archives of medical science : AMS · 2016
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marek PawlikowskiDepartment of Immunoendocrinology, Chair of Endocrinology, Medical University of Lodz, Lodz, Poland.
Maria JaranowskaDepartment of Neuroendocrinology, Chair of Laboratory Medicine, Medical University of Lodz, Lodz, Poland.
Hanna PisarekDepartment of Neuroendocrinology, Chair of Laboratory Medicine, Medical University of Lodz, Lodz, Poland.
Robert KubiakDepartment of Pathology of Tumors, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
Julita Fuss-ChmielewskaDepartment of Neuroendocrinology, Chair of Laboratory Medicine, Medical University of Lodz, Lodz, Poland.
Katarzyna WinczykDepartment of Neuroendocrinology, Chair of Laboratory Medicine, Medical University of Lodz, Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn normal conditions follicle-stimulating hormone receptors (FSHR) are expressed in the ovary and the testis. They can also be expressed in gonadal tumors. However, recently we have found FSHR immunostaining in pituitary adenomas, adrenal tumors and neuroendocrine tumors (carcinoids). The aim of this study was to determine whether the same occurs in thyroid tumors. MATERIAL AND

methodsThirty-six samples of surgically excised thyroids were examined. Follicle-stimulating hormone receptors immunostaining was performed on paraffin sections using the rabbit anti-human FSHR polyclonal antibody raised against a 1-190 amino acid sequence from the human FSHR (sc-13935, Santa Cruz).

resultsNormal thyroid follicles do not show immunopositivity for FSHR. The same concerns the majority of benign lesions, diagnosed as hyperplasia nodularis or thyroid adenomas. However, positive FSHR immunostaining in some follicles was observed. In all but one thyroid cancer (15 papillary, 10 follicular cancers and one case of anaplastic thyroid cancer) 10-100% of tumor cells exhibit positive FSHR immunostaining. In about 40% of samples FSHR immunoreactivity can be observed also in the endothelia of intrathyroidal blood vessels. This immunopositivity was more frequent in the samples of thyroid cancers (13/27) than in benign lesions (2/9).

conclusionsEctopic positive FSHR immunostaining is also present in thyroid cancers, and, to a lesser degree, in benign lesions but not in the normal thyroid epithelium.

Indexed as

follicular cancernodular hyperplasiapapillary cancer

Identifiers

PMID26788096
PMCPMC4697062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.